Prime Medicine Inc (NASDAQ: PRME) kicked off on Tuesday, down -8.62% from the previous trading day, before settling in for the closing price of $2.90. Over the past 52 weeks, PRME has traded in a range of $2.25-$9.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. While this was happening, its average annual earnings per share was recorded 26.60%. With a float of $51.92 million, this company’s outstanding shares have now reached $131.16 million.
Let’s determine the extent of company efficiency that accounts for 234 employees. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 31.03%.
Prime Medicine Inc (PRME) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.17% during the next five years compared to -193.88% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Take a look at Prime Medicine Inc’s (PRME) current performance indicators. Last quarter, stock had a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 434.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Looking closely at Prime Medicine Inc (NASDAQ: PRME), its last 5-days average volume was 1.13 million, which is a jump from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 53.00%. Additionally, its Average True Range was 0.26.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 16.26%, which indicates a significant decrease from 36.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.08% in the past 14 days, which was higher than the 83.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.87, while its 200-day Moving Average is $4.31. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $2.87. Second resistance stands at $3.10. The third major resistance level sits at $3.25. If the price goes on to break the first support level at $2.49, it is likely to go to the next support level at $2.34. Should the price break the second support level, the third support level stands at $2.11.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
The company with the Market Capitalisation of 347.58 million has total of 131,161K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -198,130 K annual income. Company’s last quarter sales were recorded 210 K and last quarter income was -52,520 K.
